Massachusetts Financial Services Co. MA bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 300,579 shares of the company's stock, valued at approximately $10,148,000. Massachusetts Financial Services Co. MA owned 0.19% of Tempus AI as of its most recent SEC filing.
Several other large investors also recently modified their holdings of TEM. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the fourth quarter worth $34,000. Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the period. First Horizon Advisors Inc. increased its holdings in Tempus AI by 207.9% in the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after acquiring an additional 1,108 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Tempus AI in the 4th quarter valued at about $67,000. Finally, IFP Advisors Inc purchased a new stake in Tempus AI during the fourth quarter valued at about $76,000. Hedge funds and other institutional investors own 24.22% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. Bank of America boosted their price target on shares of Tempus AI from $54.00 to $60.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Loop Capital cut their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Needham & Company LLC reiterated a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a research note on Thursday. Guggenheim restated a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Tempus AI currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.
View Our Latest Report on TEM
Insider Activity
In related news, major shareholder Bradley A. Keywell sold 265,000 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the transaction, the insider now owns 15,218,365 shares of the company's stock, valued at approximately $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nadja West sold 809 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $51.11, for a total transaction of $41,347.99. Following the sale, the director now directly owns 37,705 shares of the company's stock, valued at approximately $1,927,102.55. The trade was a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,581,969 shares of company stock valued at $316,538,582 over the last three months.
Tempus AI Stock Up 4.5 %
Shares of TEM traded up $1.83 on Friday, hitting $42.12. 8,540,487 shares of the stock traded hands, compared to its average volume of 5,511,880. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The business has a 50 day simple moving average of $56.19 and a 200 day simple moving average of $50.92. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.
Tempus AI Company Profile
(
Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
